Faizel Patel – 17/06/2020
Health Minister Dr Zweli Mkhize says he is extremely excited that there has been an important breakthrough in one of the therapeutic trials for COVID-19 management.
On Tuesday, a statement was issued from the chief investigators of the RECOVERY trial, a UK-based adaptive trial of various potential treatments for Covid-19, one of which was a systemic corticosteroid (dexamethasone, prednisolone or hydrocortisone).
Mkhize says the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial has published results on the therapeutic merits of low dose dexamethasone which are extremely promising and are easily implementable in the country.
“Dexamethasone is a well known and widely used steroid which has potent anti-inflammatory properties. It is used in allergic reactions, asthma and other conditions where the inflammatory component of the disease needs to be controlled for better outcomes.”
Mkhize says he is very pleased that the Ministerial Advisory Committee on COVID-19 has issued an advisory pertaining to the clinical applications of these breaking study results.
In terms of the advisory, the MAC says the full publication of the RECOVERY trial is eagerly awaited because there are important aspects of the results that is needed to make a full assessment of the data.
0 Comments